argenx | argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG We are pleased to share an important update from argenx regarding the treatment landscape for generalized myasthenia gravis (gMG). The U.S. Food and Drug Administration (FDA) has approved a label expansion for VYVGART (efgartigimod… Read more »
Partners and Friends of Conquer MG
